Expression of IL-26 Predicts Prognosis of Patients with Hepatocellular Carcinoma after Surgical Resection.

Zhi-Feng Xi,Seogsong Jeong,Chen-Chen Wang,Hong-Jie Li,Han Guo,Jie Cai,Jia-Xin Li,Xiao-Ni Kong,Ying Tong,Qiang Xia

DOI: https://doi.org/10.1016/j.hbpd.2019.03.006

IF: 3.355

2019-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:Background: There is no data regarding prognostic impact of interleukin (IL)-26 on outcomes of patients with hepatocellular carcinoma (HCC). The present study aimed to evaluate the prognostic impact of IL-26 on HCC patients undergoing liver resection. Methods: From 2003 to 2008, 122 patients with HCC who received surgical curative resection were enrolled. Patients were stratified into IL-26-upper and -lower groups according to the median expression level from immunohistochemical staining of resected specimens. Prognostic impact of IL-26 was estimated using Kaplan-Meier curves. Univariate and multivariate analyses were performed to evaluate time-dependent prognostic impact and independency of IL-26. Demographic and clinical factors that were associated with IL-26 were comprehensively identified. Results: Prognosis of the patients with high level of IL-26 revealed to be significantly unfavorable in both cumulative recurrence-free survival (P < 0.001) and overall survival (P=0.002). Upper expression of IL-26 (HR: 1.643; 95% CI: 1.021 to 2.644; P=0.041) and microvascular invasion (HR: 3.303; 95% CI: 1.255 to 8.696; P= 0.016) were identified as significant independent prognostic factors for overall survival in the multivariable analysis. Conclusions: IL-26 is a novel prognostic factor for HCC after resection. Evaluation of IL-26 expression may be potentially valuable in clinical therapy when planning individualized follow-up schedule and evaluating candidates for prophylactic adjuvant treatment to prevent recurrence. (C) 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.